Researchers at Lund University in Sweden, have in collaboration with colleagues in Copenhagen and Singapore, mapped how the body’s own peptides act to reduce infection and inflammation by deactivating the toxic substances formed in the process.
The study is published in Nature Communications and the researchers believe their discovery could lead to new drugs against infection and inflammation, for example in wound healing.
The toxins that are neutralised, known as lipopolysaccharides (LPS), come from the bacterial cell walls and generate an inflammatory reaction. The reaction is a necessary part of our immune defence system in which our bodies respond quickly and fight invasive bacteria. However, it can be over-activated and become harmful, as observed in infected skin wounds, infections in various organs, or in the case of bacteria spreading to the blood, which can lead to sepsis.
“We know from previous studies what the task of these peptides is but now we have mapped how they proceed in gradually reducing an inflammatory reaction”, says Artur Schmidtchen, professor of dermatology and venereology at Lund University and consultant physician at Skåne University Hospital in Lund.
“By use of advanced biophysics such as nuclear magnetic resonance analysis, combined with molecular modelling and biological studies we show that these peptides form a C-shaped structure which enables the capturing and inactivation of LPS. They also simultaneously interfere with receptor-mediated inflammatory responses”, adds Rathi Saravanan, senior research fellow at Lee Kong Chian School of Medicine at Nanyang Technological University, Singapore, and first author of the study.
“Currently, most drugs aim to more or less completely block a target, such as a receptor. But that risks a deactivation of the immune defence system which can be detrimental and downright dangerous. The body’s own defence mechanisms proceed with greater caution in what is known as a transient manner: the peptides act on their target for a short time to reduce an inflammation towards normalisation. It is the natural functions of these peptides that we want to develop into new drugs”, says Artur Schmidtchen, who has been researching the field of innate immunity for over 20 years.
In addition, the peptides present in thrombin, a common blood protein, are multifunctional and can attack several targets, unlike current drugs.
The dermatology researchers now want to develop a peptide gel for improved wound healing in patient studies.
“That is the primary goal, but we will also be looking at the possibility of developing new drugs against infections in the eyes and various internal organs. This will become a new way of preventing both infection and inflammation without using antibiotics.”
The Latest on: Peptides
via Google News
The Latest on: Peptides
- Immunotherapies, new gut peptides show promise for cardiometabolic diseaseson December 5, 2021 at 5:08 am
Emerging data suggest immunotherapies and novel peptides that target gut inflammation could serve as complementary agents to available diabetes drugs to more effectively target cardiometabolic ...
- Enteral Collagen Peptide Protein Market - Global Opportunity Analysis and Industry Forecast, 2021-2030 - ResearchAndMarkets.comon December 2, 2021 at 6:52 am
The “Enteral Collagen Peptide Protein Market by Form, Age Group and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030” report has been added to ResearchAndMarkets.com’s offering.
- Comparison of peptides from human cardiac proteins and SARS-CoV-2 proteinson December 1, 2021 at 4:03 am
A new study has been published on the bioRxiv* preprint server that studied whether linear peptides contained in proteins (primarily expressed in the heart) also occur in the SARS-CoV-2 proteome.
- Peptides and Heparin Market Surveys, Opportunity, Growth and Forecast by End-use Industry 2021-2031on November 30, 2021 at 5:04 am
Sales of Peptides and Heparin devices are soaring rapidly. The Demand analysis of Peptides and Heparin Market offers a comprehensive analysis of diverse features, demand, product developments, revenue ...
- Notice of Allowance Issued for Method of Treating Cytokine Storm Using Melanocortin-Specific Peptideon November 30, 2021 at 4:30 am
Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide ...
- An AI Finds Superbug-Killing Potential in Human Proteinson November 29, 2021 at 11:00 pm
A team scoured the human proteome for antimicrobial molecules and found thousands, plus a surprise about how animals evolved to fight infections.
- Are Peptides Legal To Buy In Australia?on November 29, 2021 at 9:33 am
Can Peptides be used in Australia? It is legal to supply and use peptides in Australia. However, they are classified as Schedule 4 medications, meaning that they must be prescribed by a doctor for ...
- Recombinant Peptides Market Size 2021 drivers, challenges, Top Countries Data and their impact on growth and demand forecasts in 2024on November 27, 2021 at 4:37 am
Recombinant Peptides Market 2021 By Type (Glucagon, Calcitonin, Others,), By Application ( Oncology, Blood Disorders, Infectious Diseases, Autoimmune Diseases, Others ) Geography (North America ...
- Global Antimicrobial Peptides Market – Opportunity Analysis and Industry Forecast 2026on November 24, 2021 at 7:54 am
Global Antimicrobial Peptides Market Report added at Market Study Report offers industry size, share, growth, trends and forecast analysis up to 2026. Global Antimicrobial Peptides Market also covers ...
via Bing News